Riskpilot← Back to searchSign inGet full accessROSENKRANTZ FYSIOTERAPI & MANUELL TERAPI DA
DAActiveOrg 971448601Bryggen 13, 5003 BergenFysioterapitjeneste · NACE 86902Est. 20011 employees
Revenue 2022
NOK 2,3M
+4% vs 2021
EBITDA margin
-0.9%
-1220% vs 2021
Equity ratio
67.4%
Financial strength
Net profit 2022
NOK -41K
-120% vs 2021
| Revenue | NOK 2,3M | +4% |
| EBITDA | NOK -21K | -1220% |
| Net profit | NOK -41K | -120% |
| Total assets | NOK 590K | -23% |
| Equity | NOK 398K | -9% |
| Employees | 1 | — |
Legal name
ROSENKRANTZ FYSIOTERAPI & MANUELL TERAPI DA
Org number
971448601
Legal form
Ansvarlig Selskap Med Delt Ansvar
NACE code
86902 · Fysioterapitjeneste
Founded
8. september 2001
Share capital
—
Employees
1 (FTE)
VAT registered
No
Audit selected
No
Last report
2022-12-31
Financial year
January – December
Signatory rights
Deltakerne hver for seg.
Company purpose
Drift av fellesfunksjoner i gruppepraksis i fysioterapi og virksomhet som står i forbindelse med dette. Selve fysioterapivirksomheten drives av den enkelte deltaker for dennes regning og risiko.
Address
Bryggen 13, 5003 Bergen
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| Revenue | 2 177 | 2 282 | 2 307 | 2 200 | 2 292 |
| Staff expenses | −405 | −445 | −402 | −462 | −453 |
| EBITDA | 44 | −170 | 73 | 2 | −21 |
| Depreciation & amort. | −29 | −8 | −15 | −18 | −18 |
| EBIT | 14 | −179 | 58 | −16 | −39 |
| Net financials | −2 | −1 | −2 | −2 | −2 |
| Profit before tax | 12 | −180 | 56 | −19 | −41 |
| Tax | −0 | −0 | −0 | −0 | −0 |
| Net profit | 12 | −180 | 56 | −19 | −41 |
| Item | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| Total assets | 750 | 655 | 591 | 762 | 590 |
| Equity | 581 | 401 | 457 | 439 | 398 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 169 | 253 | 134 | 323 | 192 |
| Total debt | 169 | 253 | 134 | 323 | 192 |
EBITDA margin
-0.9%
This company
15.8%
Market median
-106% vs market
20182022
Equity ratio
67.4%
This company
38.2%
Market median
+76% vs market
20182022
Return on equity
-10.3%
This company
18.4%
Market median
-156% vs market
20182022
Net profit margin
-1.8%
This company
8.1%
Market median
-122% vs market
20182022
Asset turnover
3.88×
This company
1.12×
Market median
+246% vs market
20182022
Debt / equity
0.48×
This company
0.62×
Market median
+23% vs market
20182022
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Brønnøysundsregistrene · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Brønnøysundsregistrene · Period 2018-01-01 – 2018-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
DM Contact Person | Contact Person | 2021 |
No data on file.
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 0% | 0% | 2021 | |
| Individual | 0% | 0% | 2020 | |
| Company | 0% | 0% | 2021 | |
| Individual | 0% | 0% | 2021 | |
| Individual | 0% | 0% | 2020 | |
| Company | 0% | 0% | 2021 | |
| Individual | 0% | 0% | 2021 | |
| Individual | 0% | 0% | 2021 | |
| Individual | 0% | 0% | 2021 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of ROSENKRANTZ FYSIOTERAPI & MANUELL TERAPI DA also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Dag-Eivind Midtkandal Igland | Contact Person | 0 companies |